These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25736998)

  • 1. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
    Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
    Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.
    Xing W; Ai J; Jin S; Shi Z; Peng X; Wang L; Ji Y; Lu D; Liu Y; Geng M; Hu Y
    Eur J Med Chem; 2015 May; 95():302-12. PubMed ID: 25827399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
    Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
    Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
    Albrecht BK; Harmange JC; Bauer D; Berry L; Bode C; Boezio AA; Chen A; Choquette D; Dussault I; Fridrich C; Hirai S; Hoffman D; Larrow JF; Kaplan-Lefko P; Lin J; Lohman J; Long AM; Moriguchi J; O'Connor A; Potashman MH; Reese M; Rex K; Siegmund A; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Bellon SF
    J Med Chem; 2008 May; 51(10):2879-82. PubMed ID: 18426196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of triazolopyridazinones as potent p38α inhibitors.
    Herberich B; Jackson C; Wurz RP; Pettus LH; Sherman L; Liu Q; Henkle B; Saris CJ; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1226-9. PubMed ID: 22196117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
    Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
    Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
    ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
    J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
    She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors.
    Liu X; Kou J; Xiao Z; Tian F; Hu J; Zheng P; Zhu W
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29949931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aminopyrimidine derivatives as inhibitors of the TAM family.
    Traoré T; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
    Eur J Med Chem; 2013; 70():789-801. PubMed ID: 24239626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.